Reata Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Reata Pharmaceuticals

08/11/2022 14:33

* Reata Pharmaceuticals Inc  RETA.OQ  reported a quarterly
adjusted loss of $2.16​​ per share for the quarter ended in
September. The mean expectation of ten analysts for the quarter
was for a loss of $2.18 per share.
    * Revenue fell 92.7% to $540.00 thousand from a year ago;
analysts
expected $645.25 thousand. 
    * Reata Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $2.16​.
    * The mean earnings estimate of analysts had risen by
about 0.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Reata Pharmaceuticals Inc shares had risen by 38.9% this
quarter and gained 32.3% so far this year.
    * The company reported a quarterly loss of $79 million.
    * Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $49.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 02:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -2.18          -2.16          Beat
 Jun. 30 2022      -2.02          -2.02          Met
 Mar. 31 2022      -2.17          -2.03          Beat
 Dec. 31 2021      -2.31          -2.35          Missed